Click here to close
Hello! We notice that you are using Internet Explorer, which is not supported by Xenbase and may cause the site to display incorrectly.
We suggest using a current version of Chrome,
FireFox, or Safari.
J Neurophysiol
2009 Aug 01;1022:1254-64. doi: 10.1152/jn.00346.2009.
Show Gene links
Show Anatomy links
The influence of neuroactive steroid lipophilicity on GABAA receptor modulation: evidence for a low-affinity interaction.
Chisari M
,
Eisenman LN
,
Krishnan K
,
Bandyopadhyaya AK
,
Wang C
,
Taylor A
,
Benz A
,
Covey DF
,
Zorumski CF
,
Mennerick S
.
???displayArticle.abstract???
Anesthetic steroids with actions at gamma-aminobutyric acid type A receptors (GABA(A)Rs) may access transmembrane domain binding site(s) directly from the plasma cell membrane. Accordingly, the effective concentration in lipid phase and the ability of the steroid to meet pharmacophore requirements for activity will both contribute to observed steady-state potency. Furthermore, onset and offset of receptor effects may be rate limited by lipid partitioning. Here we show that several GABA-active steroids, including naturally occurring neurosteroids, of different lipophilicity differ in kinetics and potency at GABA(A)Rs. The hydrophobicity ranking predicted relative potency of GABA(A)R potentiation and predicted current offset kinetics. Kinetic offset differences among steroids were largely eliminated by gamma-cyclodextrin, a scavenger of unbound steroid, suggesting that affinity differences among the analogues are dwarfed by the contributions of nonspecific accumulation. A 7-nitrobenz-2-oxa-1,3-diazole (NBD)-tagged fluorescent analogue of the low-lipophilicity alphaxalone (C17-NBD-alphaxalone) exhibited faster nonspecific accumulation and departitioning than those of a fluorescent analogue of the high-lipophilicity (3alpha,5alpha)-3-hydroxypregnan-20-one (C17-NBD-3alpha5alphaA). These differences were paralleled by differences in potentiation of GABA(A)R function. The enantiomer of C17-NBD-3alpha5alphaA, which does not satisfy pharmacophore requirements for steroid potentiation, exhibited identical fluorescence kinetics and distribution to C17-NBD-3alpha5alphaA, but was inactive at GABA(A)Rs. Simple simulations supported our major findings, which suggest that neurosteroid binding affinity is low. Therefore both specific (e.g., fulfilling pharmacophore requirements) and nonspecific (e.g., lipid solubility) properties contribute to the potency and longevity of anesthetic steroid action.
Adam,
Cyclodextrin-derived host molecules as reversal agents for the neuromuscular blocker rocuronium bromide: synthesis and structure-activity relationships.
2002, Pubmed
Adam,
Cyclodextrin-derived host molecules as reversal agents for the neuromuscular blocker rocuronium bromide: synthesis and structure-activity relationships.
2002,
Pubmed
Agís-Balboa,
Characterization of brain neurons that express enzymes mediating neurosteroid biosynthesis.
2006,
Pubmed
Akk,
Neurosteroid access to the GABAA receptor.
2005,
Pubmed
Akk,
Mechanisms of neurosteroid interactions with GABA(A) receptors.
2007,
Pubmed
Alakoskela,
Lack of enantiomeric specificity in the effects of anesthetic steroids on lipid bilayers.
2007,
Pubmed
Belelli,
Neuroactive steroids and inhibitory neurotransmission: mechanisms of action and physiological relevance.
2006,
Pubmed
Colquhoun,
An analysis of the action of a false transmitter at the neuromuscular junction.
1977,
Pubmed
Covey,
Enantioselectivity of pregnanolone-induced gamma-aminobutyric acid(A) receptor modulation and anesthesia.
2000,
Pubmed
de Boer,
Reversal of profound rocuronium neuromuscular blockade by sugammadex in anesthetized rhesus monkeys.
2006,
Pubmed
Gasior,
Neuroactive steroids: potential therapeutic use in neurological and psychiatric disorders.
1999,
Pubmed
Hosie,
Conserved site for neurosteroid modulation of GABA A receptors.
2009,
Pubmed
Hosie,
Endogenous neurosteroids regulate GABAA receptors through two discrete transmembrane sites.
2006,
Pubmed
Jones,
Defining affinity with the GABAA receptor.
1998,
Pubmed
Kenner,
A new fluorescent probe for protein and nucleoprotein conformation. Binding of 7-(p-methoxybenzylamino)-4-nitrobenzoxadiazole to bovine trypsinogen and bacterial ribosomes.
1971,
Pubmed
Lester,
NMDA channel behavior depends on agonist affinity.
1992,
Pubmed
Li,
Neurosteroid migration to intracellular compartments reduces steroid concentration in the membrane and diminishes GABA-A receptor potentiation.
2007,
Pubmed
Makriyannis,
How lipophilic cannabinergic ligands reach their receptor sites.
2005,
Pubmed
Mennerick,
Selective antagonism of 5alpha-reduced neurosteroid effects at GABA(A) receptors.
2004,
Pubmed
,
Xenbase
Nadeson,
Antinociceptive properties of neurosteroids III: experiments with alphadolone given intravenously, intraperitoneally, and intragastrically.
2001,
Pubmed
Pytel,
Interaction between cyclodextrin and neuronal membrane results in modulation of GABA(A) receptor conformational transitions.
2006,
Pubmed
Saalmann,
Cellular distribution of the GABAA receptor-modulating 3alpha-hydroxy, 5alpha-reduced pregnane steroids in the adult rat brain.
2007,
Pubmed
Schneider,
Fluorescent derivatives of bile salts. I. Synthesis and properties of NBD-amino derivatives of bile salts.
1991,
Pubmed
Shu,
Cyclodextrins sequester neuroactive steroids and differentiate mechanisms that rate limit steroid actions.
2007,
Pubmed
,
Xenbase
Shu,
Slow actions of neuroactive steroids at GABAA receptors.
2004,
Pubmed
,
Xenbase
Voeltz,
Structural organization of the endoplasmic reticulum.
2002,
Pubmed
Westover,
The enantiomer of cholesterol.
2004,
Pubmed
Wittmer,
Enantioselectivity of steroid-induced gamma-aminobutyric acidA receptor modulation and anesthesia.
1996,
Pubmed
,
Xenbase
Zorumski,
Potential clinical uses of neuroactive steroids.
2000,
Pubmed
Zorumski,
Enantioselective modulation of GABAergic synaptic transmission by steroids and benz[e]indenes in hippocampal microcultures.
1998,
Pubmed
